Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 39, Issue 10

Issues

Serum 90K/MAC-2BP Glycoprotein in Patients with Liver Cirrhosis and Hepatocellular Carcinoma: a Comparison with α-Fetoprotein

Palma Aurelia Iacovazzi / Adriana Trisolini / Domenico Barletta / Silvana Elba / Onofrio Giuseppe Manghisi / Mario Correale
Published Online: 2005-06-01 | DOI: https://doi.org/10.1515/CCLM.2001.155

Abstract

Glycoprotein 90K/MAC-2BP is a member of the scavenger receptor cystein-rich protein superfamily, which is thought to be involved in immune surveillance, defending the body against pathogens and cancer.

90K serum levels are elevated in patients with cancer of various origins and in viral infections, such as human immunodeficiency virus and hepatitis C virus (HCV). Because in patients with HCV-related cirrhosis the incidence of hepatocellular carcinoma (HCC) is high, in the present paper we examined, by means of an enzyme-linked immunosorbent assay, the 90K serum levels in 103 patients with liver cirrhosis, and in 69 with HCC, and compared them to α-fetoprotein, the reference tumor marker for this neoplasm.

Serum levels of 90K (cut-off 14 μg/ml) were elevated both in cirrhosis (39%) and HCC (46%) compared to controls (14.1 μg/ml vs. 10.6 μg/ml in cirrhosis, and 14.8 μg/ml vs. 9.1 μg/ml in HCC, p≤0.001). There was a significant association with the presence of anti-HCV antibodies. 90K was found to be a non-specific tumor marker which is complementary to α-fetoprotein on the basis of its probable different biological significance. In fact, 74% of HCC patients had at least one positive marker. Combined use of 90K and α-fetoprotein could improve the sensitivity of a single test in the diagnosis of HCC.

About the article

Published Online: 2005-06-01

Published in Print: 2001-10-23


Citation Information: Clinical Chemistry and Laboratory Medicine, Volume 39, Issue 10, Pages 961–965, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2001.155.

Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Vanesa Gabriela Martínez, Søren Kragh Moestrup, Uffe Holmskov, Jan Mollenhauer, Francisco Lozano, and David R. Sibley
Pharmacological Reviews, 2011, Volume 63, Number 4, Page 967
[2]
Tianhui Liu, Yameng Sun, Jialing Zhou, Fang Yang, Xia Zou, Lin Wang, Xiaoning Wu, Yongpeng Chen, Hongxin Piao, Lungen Lu, Wei Jiang, Youqing Xu, Bo Feng, Yuemin Nan, Wen Xie, Guofeng Chen, Huanwei Zheng, Hai Li, Huiguo Ding, Hui Liu, Tailing Wang, Xiaojuan Ou, Shanshan Wu, Yuanyuan Kong, Ping Wang, Min Cong, Yan Zhang, Hong You, and Jidong Jia
Journal of Medical Virology, 2019, Volume 91, Number 8, Page 1499
[3]
Megumi Fukamachi, Atsushi Kasamatsu, Yosuke Endo-Sakamoto, Kazuaki Fushimi, Hiroki Kasama, Manabu Iyoda, Yasuyuki Minakawa, Masashi Shiiba, Hideki Tanzawa, and Katsuhiro Uzawa
Experimental Cell Research, 2018
[4]
P.A. Iacovazzi, V. Guerra, S. Elba, F. Sportelli, O.G. Manghisi, and M. Correale
The International Journal of Biological Markers, 2003, Volume 18, Number 3, Page 222
[5]
Masanori Atsukawa, Akihito Tsubota, Tomomi Okubo, Taeang Arai, Ai Nakagawa, Norio Itokawa, Chisa Kondo, Keizo Kato, Tsutomu Hatori, Hiroshi Hano, Tsunekazu Oikawa, Naoya Emoto, Masanori Abe, Masayoshi Kage, and Katsuhiko Iwakiri
Hepatology Research, 2018
[6]
Malu Polanski and N. Leigh Anderson
Biomarker Insights, 2006, Volume 1, Page 117727190600100
[7]
Chih-Ching Wu, Chia-Wei Hsu, Chi-De Chen, Chia-Jung Yu, Kai-Ping Chang, Dar-In Tai, Hao-Ping Liu, Wen-Hui Su, Yu-Sun Chang, and Jau-Song Yu
Molecular & Cellular Proteomics, 2010, Volume 9, Number 6, Page 1100
[8]
Heinz Läubli, Frederico Alisson-Silva, Michal A. Stanczak, Shoib S. Siddiqui, Liwen Deng, Andrea Verhagen, Nissi Varki, and Ajit Varki
Journal of Biological Chemistry, 2014, Volume 289, Number 48, Page 33481
[9]
Ryu Sasaki, Kazumi Yamasaki, Seigo Abiru, Atsumasa Komori, Shinya Nagaoka, Akira Saeki, Satoru Hashimoto, Shigemune Bekki, Yuki Kugiyama, Atsushi Kuno, Masaaki Korenaga, Akira Togayachi, Makoto Ocho, Masashi Mizokami, Hisashi Narimatsu, Tatsuki Ichikawa, Kazuhiko Nakao, Hiroshi Yatsuhashi, and Ming-Lung Yu
PLOS ONE, 2015, Volume 10, Number 6, Page e0129053
[10]
Masayuki Mizuno, Toshihide Shima, Hirohisa Oya, Yasuhide Mitsumoto, Chiemi Mizuno, Satoshi Isoda, Mizue Kuramoto, Masanori Taniguchi, Masashi Noda, Kyoko Sakai, Noriyuki Koyama, and Takeshi Okanoue
Hepatology Research, 2017, Volume 47, Number 2, Page 216
[11]
Tianhua Liu, Denghe Liu, Riqiang Liu, Hucong Jiang, Guoquan Yan, Wei Li, Lu Sun, Shu Zhang, Yinkun Liu, and Kun Guo
Scientific Reports, 2017, Volume 7, Page 38918
[12]
Abdel Hady A. Abdel Wahab, Medhat S. El-Halawany, Ahmad A. Emam, Ammar Elfiky, and Zakaria Y. Abd Elmageed
Biomarkers, 2016, Page 1
[13]
[15]
Gustavo Ferrín, Isidora Ranchal, Camilo Llamoza, Manuel L. Rodríguez-Perálvarez, Antonio Romero-Ruiz, Patricia Aguilar-Melero, Pedro López-Cillero, Javier Briceño, Jordi Muntané, José L. Montero-Álvarez, and Manuel De la Mata
Liver International, 2014, Volume 34, Number 3, Page 438
[16]
Juan Casado-Vela, Teresa Gómez del Pulgar, Arancha Cebrián, Nestor Álvarez-Ayerza, and Juan Carlos Lacal
Expert Review of Proteomics, 2011, Volume 8, Number 3, Page 347
[17]
Jorge A. Marrero
Clinics in Liver Disease, 2005, Volume 9, Number 2, Page 235
[18]
Kin Jip Cheung, Kelly Tilleman, Dieter Deforce, Isabelle Colle, Christophe Moreno, Thierry Gustot, and Hans Van Vlierberghe
European Journal of Gastroenterology & Hepatology, 2011, Volume 23, Number 8, Page 701
[19]
Palma A. Iacovazzi, Maria Notarnicola, Maria G. Caruso, Vito Guerra, Silvia Frisullo, Donato F. Altomare, and Mario Correale
Immunopharmacology and Immunotoxicology, 2010, Volume 32, Number 1, Page 160
[20]
Palma A. Iacovazzi, Raffaele Cozzolongo, Elsa Lanzillotta, Stefania Frisullo, Vito Guerra, and Mario Correale
Immunopharmacology and Immunotoxicology, 2008, Volume 30, Number 4, Page 687
[21]
Annarita Farina, Jean-Marc Dumonceau, and Pierre Lescuyer
Expert Review of Proteomics, 2009, Volume 6, Number 3, Page 285
[22]
Ji Hee Lee, Myung Suk Park, and Ik Joo Chung
Immune Network, 2010, Volume 10, Number 6, Page 206
[23]
Donna M. Peehl, Zuxiong Chen, and Rosalie Nolley
The Prostate, 2011, Volume 71, Number 1, Page 26
[24]
Kin Jip Cheung, Louis Libbrecht, Kelly Tilleman, Dieter Deforce, Isabelle Colle, and Hans Van Vlierberghe
European Journal of Gastroenterology & Hepatology, 2010, Volume 22, Number 9, Page 1066
[25]
K. J. Cheung, K. Tilleman, D. Deforce, I. Colle, and H. Van Vlierberghe
Journal of Viral Hepatitis, 2009, Volume 16, Number 6, Page 418
[26]
Chih-Ching Wu, Kun-Yi Chien, Ngan-Ming Tsang, Kai-Ping Chang, Sheng-Po Hao, Chuang-Hui Tsao, Yu-Sun Chang, and Jau-Song Yu
PROTEOMICS, 2005, Volume 5, Number 12, Page 3173
[27]
Jens Koopmann, Paul J. Thuluvath, Marianna L. Zahurak, Troels Z. Kristiansen, Akhilesh Pandey, Richard Schulick, Pedram Argani, Manuel Hidalgo, Stefano Iacobelli, Michael Goggins, and Anirban Maitra
Cancer, 2004, Volume 101, Number 7, Page 1609

Comments (0)

Please log in or register to comment.
Log in